Yakira Capital Management Inc. Buys New Shares in Kenvue Inc. $KVUE

Yakira Capital Management Inc. bought a new stake in Kenvue Inc. (NYSE:KVUE) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 47,857 shares of the company’s stock, valued at approximately $826,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Elyxium Wealth LLC acquired a new position in Kenvue in the fourth quarter valued at $26,000. Physician Wealth Advisors Inc. increased its stake in Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after purchasing an additional 618 shares during the last quarter. SBI Securities Co. Ltd. increased its stake in Kenvue by 82.4% in the fourth quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock valued at $39,000 after purchasing an additional 1,027 shares during the last quarter. Leonteq Securities AG acquired a new position in Kenvue in the fourth quarter valued at $45,000. Finally, Quarry LP acquired a new stake in Kenvue during the fourth quarter worth about $76,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Kenvue

In other news, General Counsel Matthew Orlando sold 38,491 shares of the company’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.59% of the stock is owned by insiders.

Kenvue Stock Performance

Shares of NYSE:KVUE opened at $18.13 on Monday. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $22.87. The business has a 50-day moving average of $17.43 and a two-hundred day moving average of $17.54. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70. The firm has a market capitalization of $34.80 billion, a PE ratio of 21.32, a P/E/G ratio of 1.38 and a beta of 0.54.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.05. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The company had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $3.84 billion. During the same quarter in the prior year, the business earned $0.24 earnings per share. The company’s revenue was up 4.5% compared to the same quarter last year. As a group, research analysts forecast that Kenvue Inc. will post 1.16 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th were given a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, May 13th. This represents a $0.83 annualized dividend and a dividend yield of 4.6%. Kenvue’s dividend payout ratio is presently 97.65%.

Analyst Ratings Changes

Several brokerages have commented on KVUE. UBS Group dropped their price target on Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research note on Tuesday, April 7th. Barclays dropped their price target on Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 14th. Zacks Research upgraded Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 8th. Argus upgraded Kenvue to a “hold” rating in a research note on Friday, March 6th. Finally, Weiss Ratings lowered Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, May 29th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $19.33.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.